This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Astrazeneca Ab. Active years: 2022-2026.
Company Filing History:
Years Active: 2022-2026
Title: Erica Goldsmith: Innovator in Cardiovascular Treatments
Introduction
Erica Goldsmith is a prominent inventor based in Cambridge, GB. She has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for cardiovascular diseases. Her innovative work has garnered attention in the scientific community and beyond.
Latest Patents
Erica Goldsmith holds a patent for PCSK9 inhibitors and methods of use thereof. This invention relates to novel heteroaryl compounds of Formula (I) and pharmaceutical preparations thereof. The invention further addresses methods of treating or preventing cardiovascular diseases, as well as methods for treating sepsis or septic shock, using the novel heterocyclic compounds disclosed in her patent. She has 1 patent to her name.
Career Highlights
Goldsmith is currently employed at AstraZeneca AB, a leading global biopharmaceutical company. Her role at AstraZeneca allows her to work on groundbreaking research and development projects that aim to improve patient outcomes in cardiovascular health.
Collaborations
Throughout her career, Erica has collaborated with notable colleagues, including Michael H Serrano-Wu and Mark Chambers. These partnerships have enhanced her research and contributed to the advancement of innovative treatments in her field.
Conclusion
Erica Goldsmith is a trailblazer in the pharmaceutical industry, with her work on PCSK9 inhibitors paving the way for new treatments for cardiovascular diseases. Her contributions continue to impact the health sector positively.